Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Key Takeaways

• 35% lower death risk vs nab‑paclitaxel alone (HR 0.65).
• Median overall survival extended by 4.1 months (16.0 vs 11.9).
• Added as preferred NCCN regimen for platinum‑resistant ovarian cancer.
• First FDA‑approved selective glucocorticoid receptor antagonist (SGRA).
• Trial enrolled 381 patients across 7 continents, no biomarker requirement.

Pulse Analysis

The phase 3 ROSELLA trial has delivered the most compelling survival data in decades for platinum‑resistant ovarian cancer. Patients receiving Lifyorli (relacorilant) together with nab‑paclitaxel saw a 35 percent reduction in the risk of death and lived, on average, 4.1 months longer than those on chemotherapy alone. The hazard ratio of 0.65 and a statistically significant p‑value of 0.0004 underscore the robustness of the findings, which were presented at the Society of Gynecologic Oncology meeting and published in The Lancet.

Beyond the clinical numbers, the approval reshapes the therapeutic landscape. By entering the NCCN Guidelines as a preferred regimen, Lifyorli gains immediate credibility among oncologists and insurers, positioning it ahead of traditional cytotoxic combos that lack a clear survival advantage. As the first FDA‑cleared selective glucocorticoid receptor antagonist, it differentiates Corcept from competitors and opens a pathway for reimbursement, potentially accelerating adoption across U.S. cancer centers.

The broader implication lies in validating cortisol modulation as a viable strategy against chemotherapy resistance. Corcept’s pipeline now extends to other solid tumors where glucocorticoid signaling drives tumor survival, and a European marketing‑authorisation application is already underway. Investors and analysts are likely to view the ROSELLA success as a catalyst for future partnerships and a template for expanding SGRA therapy into additional indications, reinforcing Corcept’s position at the intersection of endocrinology and oncology.